Pharmacist implementation of a treatment pathway for atrial fibrillation in care home residents

Pharmacist-led intervention for atrial fibrillation in long-term care.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14747952

Enrollment

Registered

2020-10-02

Start date

2020-11-01

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation Circulatory System

Interventions

This study is a pilot and feasibility study where participants will be randomly allocated to one of two treatment groups, the intervention or control group. In the intervention group, participants’ m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged =65 years 2. Diagnosis of AF 3. Resident in a care home in Liverpool, South Sefton, Southport or Formby

Exclusion criteria

Exclusion criteria: 1. Diagnosed with aphasia 2. Short-stay care home residents (expected stay <6 months) 3. Receiving end-of-life care 4. Non-English speaking

Design outcomes

Primary

Measure	Time frame
1. Care home recruitment rate measured during the 6 month recruitment period from the initial study start date 2. Participant recruitment rate measured during the 6 month recruitment period from the initial study start date 3. Participant retention rate measured at 6 months and 12 months 4. Number and nature of pharmacist medication-related recommendations (classified by type and drug(s) involved) measured at baseline 5. GP implementation of pharmacist recommendations measured at 6 months 6. Completion rate of participant self-complete questionnaires to assess generic health-related quality of life (EQ-5D-5L) and disease-specific quality of life (Atrial Fibrillation Effect on Quality of Life, AFEQT) measured at baseline and 6 months 7. Completion rate of researcher administered assessments requiring participant input to assess frailty (Edmonton Frail Scale, EFS) and cognitive function (6-item Cognitive Impairment Test, 6-CIT) measured at baseline and 6 months 8. Completion rate of GP questionnaire sent to ascertain the outcome(s) of pharmacist medicines recommendation(s) measured at 6 months 9. Percentage of missing/incomplete data for all questionnaires/assessments measured at baseline and 6 months	—

Measure

Time frame

1. Care home recruitment rate measured during the 6 month recruitment period from the initial study start date 2. Participant recruitment rate measured during the 6 month recruitment period from the initial study start date 3. Participant retention rate measured at 6 months and 12 months 4. Number and nature of pharmacist medication-related recommendations (classified by type and drug(s) involved) measured at baseline 5. GP implementation of pharmacist recommendations measured at 6 months 6. Completion rate of participant self-complete questionnaires to assess generic health-related quality of life (EQ-5D-5L) and disease-specific quality of life (Atrial Fibrillation Effect on Quality of Life, AFEQT) measured at baseline and 6 months 7. Completion rate of researcher administered assessments requiring participant input to assess frailty (Edmonton Frail Scale, EFS) and cognitive function (6-item Cognitive Impairment Test, 6-CIT) measured at baseline and 6 months 8. Completion rate of GP questionnaire sent to ascertain the outcome(s) of pharmacist medicines recommendation(s) measured at 6 months 9. Percentage of missing/incomplete data for all questionnaires/assessments measured at baseline and 6 months

—

Secondary

Measure	Time frame
1. Generic health-related quality of life (EQ-5D-5L) and disease-specific quality of life (AFEQT) measured at baseline and 6 months 2. Health-related events (stroke, major bleeding, clots in the body, falls, hospitalisation and death) measured at 6 months and 12 months 3. Frailty measured using the EFS, Rockwood Clinical Frailty Scale and the electronic Frailty Index at baseline and 6 months 4. Cognitive function measured using the 6-CIT at baseline and 6 months 5. Level of dependence in activities of daily living measured using the Barthel Index of Activities of Daily Living at baseline and 6 months	—

Measure

Time frame

1. Generic health-related quality of life (EQ-5D-5L) and disease-specific quality of life (AFEQT) measured at baseline and 6 months 2. Health-related events (stroke, major bleeding, clots in the body, falls, hospitalisation and death) measured at 6 months and 12 months 3. Frailty measured using the EFS, Rockwood Clinical Frailty Scale and the electronic Frailty Index at baseline and 6 months 4. Cognitive function measured using the 6-CIT at baseline and 6 months 5. Level of dependence in activities of daily living measured using the Barthel Index of Activities of Daily Living at baseline and 6 months

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 9, 2026